Meeting
2016 ASCO Annual Meeting
Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.
Authors
Christian M. Kurbacher
Gynecologic Center Bonn-Friedensplatz, Bonn, Germany
Christian M. Kurbacher , Christian A. Eichler , Annegret Barbara Quade , Gerhard Kunstmann , Susanne Herz , Jutta Anna Kurbacher , Mathias R. Warm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 597)
DOI
10.1200/JCO.2016.34.15_suppl.597
Abstract #
597
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.
First Author: Zongbi Yi
Poster
2016 ASCO Annual Meeting
miR-125a-induced cellular switch to elicit a response to anti-HER2 targeted therapy in gastric cancer cells.
First Author: Elad Hikri
Poster
2015 ASCO Annual Meeting
Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.
First Author: Christian M. Kurbacher
Poster
2015 Gastrointestinal Cancers Symposium
Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
First Author: Salvatore Siena